UCB SA (UCB)-Financial and Strategic SWOT Analysis Review

UCB SA (UCB)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH33857FSA
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

UCB SA (UCB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It focuses mainly on products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and Restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Apr 26,2017: UCB Selects Medidata Clinical Cloud to Support Patient-Centric Drug Development

Apr 24,2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017

Mar 24,2017: UCB General Meeting on 27 April 2017

Dec 15,2016: New appointments on UCB's Board of Directors

Oct 28,2016: UCB announces availability of prefilled pen for rheumatic diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

UCB SA-Key Facts 6

UCB SA-Key Employees 7

UCB SA-Key Employee Biographies 8

UCB SA-Major Products and Services 10

UCB SA-Pharmaceutical Pipeline Products Data 11

UCB SA, Pipeline Products by Therapy Area 11

UCB SA, Pipeline Products by Development Phase 12

UCB SA-History 13

UCB SA-Company Statement 19

UCB SA-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Joint Venture 23

Section 2-Company Analysis 24

UCB SA-Business Description 24

UCB SA-Corporate Strategy 25

UCB SA-SWOT Analysis 26

SWOT Analysis-Overview 26

UCB SA-Strengths 26

UCB SA-Weaknesses 27

UCB SA-Opportunities 28

UCB SA-Threats 29

UCB SA-Key Competitors 30

Section 3-Company Financial Ratios 31

Financial Ratios-Capital Market Ratios 31

Financial Ratios-Annual Ratios 32

Performance Chart 35

Financial Performance 35

Financial Ratios-Interim Ratios 36

Financial Ratios-Ratio Charts 37

Section 4-Company's Lifesciences Financial Deals and Alliances 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 39

UCB SA, Recent Deals Summary 40

Section 5-Company's Recent Developments 41

Apr 26, 2017: UCB Selects Medidata Clinical Cloud to Support Patient-Centric Drug Development 41

Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 42

Mar 24, 2017: UCB General Meeting on 27 April 2017 43

Dec 15, 2016: New appointments on UCB's Board of Directors 44

Oct 28, 2016: UCB announces availability of prefilled pen for rheumatic diseases 45

Sep 13, 2016: Neuropore Therapies Announces Achievement of Key Program Milestone 46

Jul 27, 2016: UCB continues to deliver on its growth strategy 47

Apr 25, 2016: UCB First Three Months Interim Report 2016 48

Apr 21, 2016: UCB underlines its commitment to improving the lives of people with Parkinson's to mark UK's Parkinson's Awareness Week 49

Apr 04, 2016: IXICO Joins Global Parkinson's Consortium 50

Section 6-Appendix 51

Methodology 51

Ratio Definitions 51

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

UCB SA, Pipeline Products by Therapy Area 11

UCB SA, Pipeline Products by Development Phase 12

UCB SA, Performance Chart (2012-2016) 35

UCB SA, Ratio Charts 37

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 38

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 39

List of Tables

UCB SA, Key Facts 6

UCB SA, Key Employees 7

UCB SA, Key Employee Biographies 8

UCB SA, Major Products and Services 10

UCB SA, Number of Pipeline Products by Therapy Area 11

UCB SA, Number of Pipeline Products by Development Stage 12

UCB SA, History 13

UCB SA, Subsidiaries 20

UCB SA, Joint Venture 23

UCB SA, Key Competitors 30

UCB SA, Ratios based on current share price 31

UCB SA, Annual Ratios 32

UCB SA, Annual Ratios (Cont...1) 33

UCB SA, Annual Ratios (Cont...2) 34

UCB SA, Interim Ratios 36

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 39

UCB SA, Recent Deals Summary 40

Currency Codes 51

Capital Market Ratios 51

Equity Ratios 52

Profitability Ratios 52

Cost Ratios 53

Liquidity Ratios 53

Leverage Ratios 54

Efficiency Ratios 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

UCB SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8071
Site License
USD 250 INR 16143
Corporate User License
USD 375 INR 24214

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com